VP
IMPL

venBio Partners’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

venBio Partners’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,759,791
Closed -$341K – 7
2023
Q4 		$341K Hold
2,759,791
– – 0.05% 7
2023
Q3 		$1.19M Hold
2,759,791
– – 0.34% 8
2023
Q2 		$3.5M Hold
2,759,791
– – 1.27% 7
2023
Q1 		$3.86M Hold
2,759,791
– – 2.14% 5
2022
Q4 		$10.3M Hold
2,759,791
– – 3.21% 5
2022
Q3 		$13.4M Hold
2,759,791
– – 3.11% 7
2022
Q2 		$25.7M Hold
2,759,791
– – 7.32% 6
2022
Q1 		$17.6M Hold
2,759,791
– – 3.9% 7
2021
Q4 		$23.8M Hold
2,759,791
– – 4.29% 6
2021
Q3 		$33.6M Hold
2,759,791
– – 3.35% 5
2021
Q2 		$24.4M Buy
+2,759,791
New +$33M 2.88% 7

venBio Partners's IMPL Position: Q1 2024 in Review

venBio Partners sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q1 2024, closing a stake of 2,759,791 shares — an estimated $341K sold.

venBio Partners first reported a position in IMPL in Q2 2021 and held it in 11 quarters. The position peaked at $33.6M in Q3 2021. 0 funds tracked by Wall St. Rank hold IMPL as of Q1 2024.

  • venBio Partners reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • venBio Partners sold 2,759,791 Impel Pharmaceuticals Inc. Common Stock shares in Q1 2024, an estimated $341K.
  • venBio Partners first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 11 quarters.
  • venBio Partners's Impel Pharmaceuticals Inc. Common Stock position peaked at $33.6M in Q3 2021.
  • 0 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q1 2024.

Based on venBio Partners's 13F filing for Q1 2024, filed 15 May 2024.